REVIEWERS: Yves Hennequin, director of business support, and Jean- Christophe Huet, director of IT for Lundbeck, France.

BACKGROUND: Lundbeck is a unique pharmaceutical company focusing solely on the treatment of diseases of the central nervous system (CNS). Our vision is to help patients suffering from neurological and psychiatric diseases within the CNS area. In addition to developing world-class pharmaceuticals, Lundbeck places great emphasis on increasing knowledge by offering education to healthcare providers, patients and their relatives. Lundbeck business and R&D focus areas are psychiatry and neurology. In the last few years we have greatly intensified our research and development activities, investing approximately 20 percent of revenue in R&D. We are the third largest pharmaceutical company in Western Europe within antidepressants and sixth largest company within sales of antipsychotics. Headquartered in Denmark, Europe is Lundbeck's home market. Lundbeck has subsidiaries in 29 countries and partner alliances in the Far East, Middle East, Latin America, North Africa and East Europe. In 2002, Lundbeck employed 4,534 employees, with 834 people in R&D. Operating in the French market since 1992, Lundbeck France markets one main product: Seropram/Citalopram, for depression and two others for psychotic disorders: Fluanxol/Flupentixol and Clopixol/Zuclopenthixol. Lundbeck France is about to launch two new products: Cipralex/Escitalopram (depression) and Ebixa/Memantine (Alzheimer). In 2002, Lundbeck France had 454 employees, with 347 in sales and 54 in R&D.

Register or login for access to this item and much more

All Information Management content is archived after seven days.

Community members receive:
  • All recent and archived articles
  • Conference offers and updates
  • A full menu of enewsletter options
  • Web seminars, white papers, ebooks

Don't have an account? Register for Free Unlimited Access